Sushil Ghimire

Sushil Ghimire

Auto-generated profile, based on publicly available information

Sushil Ghimire

Department of Internal Medicine, Reading Health System, West Reading, PA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
PKParas Karmacharya
Paras Karmacharya
DPDilli Ram Poudel
Dilli Ram Poudel
RPRanjan Pathak
Ranjan Pathak
ADAnthony A. Donato
Anthony A. Donato
SGSushil Ghimire
Sushil Ghimire
CBClifton O. Bingham
Clifton O. Bingham

28 June 2014 in Echocardiography
Verified
Journal Article
Closed access
PDF file
MAMadan Raj Aryal
Madan Raj Aryal
FHFayaz A. Hakim
Fayaz A. Hakim
SGSailu Ghimire
Sailu Ghimire
SGSushil Ghimire
Sushil Ghimire
SGSmith Giri
Smith Giri
RPRajesh Pradhan
Rajesh Pradhan

24 February 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
DPDilli Ram Poudel
Dilli Ram Poudel
PAPrakash Acharya
Prakash Acharya
SGSushil Ghimire
Sushil Ghimire
RDRashmi Dhital
Rashmi Dhital
RBRajani Bharati
Rajani Bharati

1 February 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
SNSalik Nazir
Salik Nazir
SLSaroj Lohani
Saroj Lohani
NTNiranjan Tachamo
Niranjan Tachamo
SGSushil Ghimire
Sushil Ghimire
DPDilli Ram Poudel
Dilli Ram Poudel
ADAnthony Donato
Anthony Donato

18 August 2017 in Platelets
Verified
Journal Article
Closed access
DPDilli Ram Poudel
Dilli Ram Poudel
SGSushil Ghimire
Sushil Ghimire
RDRashmi Dhital
Rashmi Dhital
DFDaniel A. Forman
Daniel A. Forman
TWTheodore E. Warkentin
Theodore E. Warkentin
Recently published reports have established a heparin-induced thrombocytopenia (HIT)-mimicking thromboembolic disorder without proximate heparin exposure, called spontaneous HIT syndrome. Although the pathophysiology remains unclear, anti-platelet factor 4 (PF4)/heparin antibodies possibly triggered by exposure to knee cartilage glycosaminoglycans or other non-heparin polyanions found on bacterial surfaces and nucleic acids have been postulated. We present a 53-year-old female receiving antithrombotic prophylaxis with aspirin following right total knee replacement surgery (without perioperative or any previous lifetime heparin exposure) who acutely presented with high-risk pulmonary embolism (PE) and right great saphenous vein thrombophlebitis on postoperative day (POD) 14; her platelet count at presentation was 13 × 109/L. Prior to diagnostic consideration of spontaneous HIT syndrome, the patient briefly received unfractionated heparin (UFH) and one dose of enoxaparin. The patient’s serum tested strongly positive for anti-PF4/heparin antibodies by two different PF4-dependent enzyme-linked immunosorbent assays (ELISAs) and by serotonin release assay (SRA). Failure of fondaparinux anticoagulation (persisting HIT-associated disseminated intravascular coagulation) prompted switching to argatroban. Severe thrombocytopenia persisted (platelet count nadir, 12 × 109/L, on POD21), and 9 days after starting argatroban symptomatic right leg deep-vein thrombosis (DVT) occurred, prompting switch to rivaroxaban. Thereafter, her course was uneventful, although platelet count recovery was prolonged, reaching 99 × 109/L by POD45 and 199 × 109/L by POD79. The patient’s serum elicited strong serotonin release in the absence of heparin (seen even with 1/32 serum dilution) that was enhanced by pharmacological concentrations of UFH (0.1 and 0.3 IU/mL) and fondaparinux (0.1–1.2 μg/mL, i.e., in vitro fondaparinux “cross-reactivity”). Ultimately, platelet count recovery was associated with seroreversion to a negative SRA (documented at POD151). Our literature review identified joint replacement surgery, specifically knee replacement, to be a relatively common trigger of spontaneous HIT syndrome. Further, including our patient case, 5 of 7 patients with spontaneous HIT syndrome post-orthopedic surgery who received treatment with argatroban developed new and/or progressive lower-limb DVT or recurrent PE despite anticoagulation with this parenteral direct thrombin inhibitor, suggesting that this patient population is at high risk of breakthrough thrombotic events despite treatment with this HIT treatment-approved anticoagulant. Our case also illustrates successful outcome with rivaroxaban for treatment of spontaneous HIT syndrome, consistent with emerging literature supporting safety and efficacy of direct oral anticoagulant therapy for treatment of acute HIT.

22 January 2014 in Echocardiography
Verified
Journal Article
Closed access
PDF file
MAMadan Raj Aryal
Madan Raj Aryal
FHFayaz A. Hakim
Fayaz A. Hakim
SGSmith Giri
Smith Giri
SGSushil Ghimire
Sushil Ghimire
APAnil Pandit
Anil Pandit
RPRajesh Pradhan
Rajesh Pradhan